Endometriosis Pathogenesis and 37 New Loci Identified Through a Multi-ancestry Genome-Wide Association Study of 1.4 Million Individuals and Multi-omics

Background
Endometriosis, a chronic inflammatory condition in which endometrial tissue proliferates outside the uterus, such as in the pelvic cavity, affects one in ten women of reproductive age. Accompanied by severe dysmenorrhea, chronic pelvic pain, and infertility, it severely disrupts daily life. The average time to diagnosis alone ranges from 7 to 10 years. This is likely due to the fact that initial symptoms are ambiguous and confirmation requires invasive procedures such as laparoscopic surgery.
Despite continuous academic tracking, the fundamental mechanism of its onset remained shrouded in mystery for a long time. There have also been criticisms that most existing studies are focused on European populations, making it difficult to apply the same standards to other ethnicities. Another long-standing limitation is the failure to reveal the correlation with systemic immune system abnormalities, as the disease was viewed only as a localized condition confined to the pelvic area. This is why global-scale multi-ancestry data and systematic biological mechanism analysis were urgently needed to comprehensively elucidate the complex characteristics of the disease.
Key Findings
An international collaborative research team, including Oxford University, conducted the largest-scale study ever by combining data from 14 global biobanks. The analysis included 1.4 million women, including 105,869 patients with endometriosis. By ensuring that non-European individuals comprised more than 30% of the total sample, geographical and racial biases in genomic research were significantly reduced.
Through multi-ancestry genome-wide association studies (GWAS), the researchers identified 80 loci that show a statistically significant association with the risk of developing endometriosis. Among these, 37 loci are novel positions not previously reported in earlier studies. Five genetic loci associated with adenomyosis, a condition in which endometrial tissue invades the uterine muscle layer, were also identified for the first time. It is also noteworthy that causal variants were distilled from over 50 disease signals using fine-mapping and colocalization techniques.
Beyond simple variant identification, the researchers also conducted multi-omics analysis encompassing the transcriptome, epigenome, and proteome. The gene networks were found to be closely intertwined not only with hormone responses but also with immune cell regulation, angiogenesis, and cell proliferation pathways. These results demonstrate that endometriosis is not a simple local lesion but a complex disease involving immune system abnormalities and tissue remodeling. The researchers calculated Polygenic Risk Scores (PRS) to precisely track correlations with comorbid conditions. The high-risk patient group showed a clear genetic tendency to overlap with the likelihood of experiencing chronic abdominal pain, migraines, and anxiety disorders. This supports the interpretation that signaling disruptions across the nervous and immune systems trigger simultaneous clinical symptoms.
Significance and Outlook
This study expanded the perspective on endometriosis from a localized abnormality centered on the pelvic cavity to a systemic immune-metabolic disease. The map of 80 identified loci serves as a decisive milestone for classifying the heterogeneity of the disease at the molecular level. From the perspective of therapeutic development, practical leads have also emerged. By conducting parallel drug repurposing analyses, the researchers determined that existing breast cancer treatments and preterm birth prevention drugs could regulate the target genes.
It is calculated that using drugs with already proven safety can significantly reduce the time and cost required for new drug development. However, hurdles to applying this to actual patient treatment clearly exist. Although non-European samples accounted for more than 30%, the proportion of African and Middle Eastern populations remains insufficient. Large-scale functional genomics experiments to demonstrate how the identified genetic variants specifically disrupt expression in lesion tissue are also cited as a follow-up challenge.
Nature Genetics, Published online: 20 November 2026; doi:10.1038/s41588-026-02810-9Multiancestry genome-wide association coupled with integrative multiomics analyses identify risk loci for endometriosis and implicate key genes and pathways underlying its pathogenesis, including roles for immune cell types and cellular proliferation.
In clinical settings, the diagnosis of endometriosis has long been tied to invasive laparoscopic surgery. The 80 loci and Polygenic Risk Scores (PRS) derived from this study are evaluated as keys to accelerating the construction of non-invasive early diagnostic screening panels. The scenario of using blood collection and genomic testing to early-screen high-risk groups among patients in their teens or early 20s presenting with unexplained chronic pelvic pain has become a realistic possibility.
Treatment strategies are also poised to reach a fundamental turning point. Beyond simple symptomatic therapies that merely suppress hormone secretion or alleviate pain, the development of targeted therapies that directly block immune cell infiltration and tissue fibrosis will gain momentum. In particular, by re-evaluating pre-approved drugs identified as drug repurposing candidates, the timeline for entering Phase 2 clinical trials can be significantly shortened, allowing individualized treatment options to be offered early to patients at risk of infertility.